Annett Holsken

Erlangen, BY, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications

Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology.

Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology.

Journal: The Journal of molecular diagnostics : JMD
Published: November 24, 2025

Extra-abdominal and intra-abdominal FET::CREM fusion mesenchymal neoplasms: comparative clinicopathological study of 9 new cases further supporting a distinct potentially aggressive sarcoma and report of novel sites.

Extra-abdominal and intra-abdominal FET::CREM fusion mesenchymal neoplasms: comparative clinicopathological study of 9 new cases further supporting a distinct potentially aggressive sarcoma and report of novel sites.

Journal: Virchows Archiv : an international journal of pathology
Published: August 03, 2024

Limited association between HRR gene alterations and HRD in molecular tumor board cancer samples: Who should be tested for HRD?

Limited association between HRR gene alterations and HRD in molecular tumor board cancer samples: Who should be tested for HRD?

Journal: International journal of cancer
Published: June 26, 2024

CTNNB1 mutations are clonal in adamantinomatous craniopharyngioma.

CTNNB1 mutations are clonal in adamantinomatous craniopharyngioma.

Journal: Neuropathology and applied neurobiology
Published: October 18, 2019

Characterization of the murine orthotopic adamantinomatous craniopharyngioma PDX model by MRI in correlation with histology.

Characterization of the murine orthotopic adamantinomatous craniopharyngioma PDX model by MRI in correlation with histology.

Journal: PloS one
Published: January 11, 2018

Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target.

Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target.

Journal: Acta neuropathologica
Published: October 16, 2017

DNA methylation-based classification of central nervous system tumours.

DNA methylation-based classification of central nervous system tumours.

Journal: Nature
Published: May 05, 2017

Rathke's Cleft Cyst as Origin of a Pediatric Papillary Craniopharyngioma.

Rathke's Cleft Cyst as Origin of a Pediatric Papillary Craniopharyngioma.

Journal: Frontiers in genetics
Published: March 10, 2017

Preclinical transgenic and patient-derived xenograft models recapitulate the radiological features of human adamantinomatous craniopharyngioma.

Preclinical transgenic and patient-derived xenograft models recapitulate the radiological features of human adamantinomatous craniopharyngioma.

Journal: Brain pathology (Zurich, Switzerland)
Published: February 08, 2017

Models of human adamantinomatous craniopharyngioma tissue: Steps toward an effective adjuvant treatment.

Models of human adamantinomatous craniopharyngioma tissue: Steps toward an effective adjuvant treatment.

Journal: Brain pathology (Zurich, Switzerland)
Published: February 03, 2017

Drug priming enhances radiosensitivity of adamantinomatous craniopharyngioma via downregulation of survivin.

Drug priming enhances radiosensitivity of adamantinomatous craniopharyngioma via downregulation of survivin.

Journal: Neurosurgical focus
Published: December 02, 2016

Expression of SRY-related HMG Box Transcription Factors (Sox) 2 and 9 in Craniopharyngioma Subtypes and Surrounding Brain Tissue.

Expression of SRY-related HMG Box Transcription Factors (Sox) 2 and 9 in Craniopharyngioma Subtypes and Surrounding Brain Tissue.

Journal: Scientific reports
Published: October 25, 2016
Showing 1-12 of 25

Last Updated: 09/26/2026